

The revision of the EU Regulations on medicines for Children and for Rare Diseases

VIRTUAL POLICY DIALOGUE 20 May 2021 | 12:00-13:30 CEST

12:00-12:05

Welcome

Guy Muller, European Fair Pricing Network & Dutch Cancer Society, [@kwf_nl](#)

12:05-12:45

Reflections on the Orphan Regulation

- Dr. Beate Wieseler, Institute for Quality and Efficiency in Health Care, [@iqwig](#)
- Prof. Dr. Wolf-Dieter Ludwig, German Medical Association, [@BAEKaktuell](#)
- Dr. Ward Rommel, ECL Access to Medicines Task Force & Stand Up to Cancer Flanders, [@WardRommel](#) [@cancerleagues](#)
- Kaja Kantorska, European Commission (DG SANTE), [@EU_Health](#)

Discussion moderated by Yannis Natsis, European Public Health Alliance, [@YNatsis](#)

12:45-13:25

Reflections on the Paediatric Regulation

- Prof. Gilles Vassal, European Society for Paediatric Oncology & Gustave Roussy Institute, [@Gilles_Vassal](#) [@SIOPEurope](#)
- Delphine Heenen, the Childhood Cancer International – Europe & KickCancer Foundation, [@Delphieheenen](#) [@cci_europe](#)
- Dr. Frank Hulstaert, Belgian Health Care Knowledge Centre, [@KCEfgov](#)
- Dr. Fabio D'Atri, European Commission (DG SANTE), [@EU_Health](#)

Discussion moderated by Yannis Natsis, European Public Health Alliance, [@YNatsis](#)

13:25-13:30

Conclusions & key takeaways

- Ingrid Stenstadvold Ross, European Fair Pricing Network & Norwegian Cancer Society [@IngridSRoss](#) [@Kreftforeningen](#)
- Olga Kozhaeva, European Society for Paediatric Oncology, [@olga_kv](#) [@SIOPEurope](#)



cancer.eu
siope.eu
epha.org
efpn.eu



@cancerleagues
@EPHA_EU
@SIOPEurope



#LetsTalkAccess
#EUPharmaStrategy
#OrphanDrugs
#Meds4Kids